{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:45:18Z","timestamp":1783118718587,"version":"3.54.6"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007314","name":"Duncan Family Institute for Cancer Prevention and Risk Assessment","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007314","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UT MD Anderson Cancer Center Colorectal Cancer Moon Shot"},{"name":"DHHS\/NCI Cancer Center Support Grant","award":["P30 CA16672-39"],"award-info":[{"award-number":["P30 CA16672-39"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["2R42CA171408-02A1"],"award-info":[{"award-number":["2R42CA171408-02A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["P50 CA221707"],"award-info":[{"award-number":["P50 CA221707"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and sulindac are effective for colorectal cancer prevention in humans and some animal models, but concerns over gastro-intestinal (GI) ulceration and bleeding limit their potential for chemopreventive use in broader populations. Recently, the combination of aspirin with a phospholipid, packaged as PL-ASA, was shown to reduce GI toxicity in a small clinical trial. However, these studies were done for relatively short periods of time. Since prolonged, regular use is needed for chemopreventive benefit, it is important to know whether GI safety is maintained over longer use periods and whether cancer prevention efficacy is preserved when an NSAID is combined with a phospholipid.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>As a first step to answering these questions, we treated seven to eight-week-old, male and female C57B\/6 <jats:italic>Apc<\/jats:italic><jats:sup><jats:italic>min\/+<\/jats:italic><\/jats:sup> mice with the NSAID sulindac, with and without phosphatidylcholine (PC) for 3-weeks. At the end of the treatment period, we evaluated polyp burden, gastric toxicity, urinary prostaglandins (as a marker of sulindac target engagement), and blood chemistries.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Both sulindac and sulindac-PC treatments resulted in significantly reduced polyp burden, and decreased urinary prostaglandins, but sulindac-PC treatment also resulted in the reduction of gastric lesions compared to sulindac alone.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Together these data provide pre-clinical support for combining NSAIDs with a phospholipid, such as phosphatidylcholine to reduce GI toxicity while maintaining chemopreventive efficacy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07311-4","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T12:03:37Z","timestamp":1599739417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9456-1682","authenticated-orcid":false,"given":"Jennifer S.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Kanikarla-Marie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Gagea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick L.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Hawk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"Dashwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenard M.","family":"Lichtenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Menter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"7311_CR1","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jama.294.8.914","volume":"294","author":"AT Chan","year":"2005","unstructured":"Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294:914\u201323.","journal-title":"JAMA"},{"key":"7311_CR2","doi-asserted-by":"publisher","first-page":"814","DOI":"10.7326\/M15-2117","volume":"164","author":"J Chubak","year":"2016","unstructured":"Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DS, et al. Aspirin for the prevention of Cancer incidence and mortality: systematic evidence reviews for the U.S. preventive services task force. Ann Intern Med. 2016;164:814\u201325.","journal-title":"Ann Intern Med"},{"key":"7311_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7326\/M16-0577","volume":"164","author":"K Bibbins-Domingo","year":"2016","unstructured":"Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statementAspirin use for the Primary Prevention of CVD and CRC. Ann Intern Med. 2016;164:836\u201345.","journal-title":"Ann Intern Med"},{"key":"7311_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0140-6736(80)90282-2","volume":"2","author":"JW Hoftiezer","year":"1980","unstructured":"Hoftiezer JW, Silvoso GR, Burks M, Ivey KJ. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man. Lancet. 1980;2:609\u201312.","journal-title":"Lancet"},{"key":"7311_CR5","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.3748\/wjg.v21.i17.5382","volume":"21","author":"C Mo","year":"2015","unstructured":"Mo C, Sun G, Lu ML, Zhang L, Wang YZ, Sun X, et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol. 2015;21:5382\u201392.","journal-title":"World J Gastroenterol"},{"key":"7311_CR6","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/jgh.12595","volume":"29","author":"N Nagata","year":"2014","unstructured":"Nagata N, Niikura R, Aoki T, Shimbo T, Kishida Y, Sekine K, et al. Colonic diverticular hemorrhage associated with the use of nonsteroidal anti-inflammatory drugs, low-dose aspirin, antiplatelet drugs, and dual therapy. J Gastroenterol Hepatol. 2014;29:1786\u201393.","journal-title":"J Gastroenterol Hepatol"},{"key":"7311_CR7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/0002-9343(86)90289-5","volume":"81","author":"MJ Stampfer","year":"1986","unstructured":"Stampfer MJ, Jakubowski JA, Deykin D, Schafer AI, Willett WC, Hennekens CH. Effect of alternate-day regular and enteric-coated aspirin on platelet aggregation, bleeding time, and thromboxane A2 levels in bleeding-time blood. Am J Med. 1986;81:400\u20134.","journal-title":"Am J Med"},{"key":"7311_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/ajg.2018.29","volume":"113","author":"L Targownik","year":"2018","unstructured":"Targownik L. Discontinuing Long-Term PPI Therapy: why, with whom, and how? Am J Gastroenterol. 2018;113:519\u201328.","journal-title":"Am J Gastroenterol"},{"key":"7311_CR9","first-page":"G561","volume":"244","author":"BA Hills","year":"1983","unstructured":"Hills BA, Butler BD, Lichtenberger LM. Gastric-mucosal barrier - hydrophobic lining to the lumen of the stomach. Am J Physiol. 1983;244:G561\u2013G8.","journal-title":"Am J Physiol"},{"key":"7311_CR10","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1126\/science.6828859","volume":"219","author":"LM Lichtenberger","year":"1983","unstructured":"Lichtenberger LM, Graziani LA, Dial EJ, Butler BD, Hills BA. Role of surface-active phospholipids in gastric cytoprotection. Science. 1983;219:1327\u20139.","journal-title":"Science"},{"key":"7311_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nm0295-154","volume":"1","author":"LM Lichtenberger","year":"1995","unstructured":"Lichtenberger LM, Wang ZM, Romero JJ, Ulloa C, Perez JC, Giraud MN, et al. Nonsteroidal Antiinflammatory drugs (Nsaids) associate with Zwitterionic phospholipids - insight into the mechanism and reversal of Nsaid-induced gastrointestinal injury. Nat Med. 1995;1:154\u20138.","journal-title":"Nat Med"},{"key":"7311_CR12","first-page":"491","volume":"62","author":"LM Lichtenberger","year":"2011","unstructured":"Lichtenberger LM, Phan T, Okabe S. Aspirin's ability to induce intestinal injury in rats is dependent on bile and can be reversed if pre-associated with phosphatidylcholine. J Physiol Pharmacol. 2011;62:491\u20136.","journal-title":"J Physiol Pharmacol"},{"key":"7311_CR13","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s11239-019-01933-7","volume":"48","author":"DJ Angiolillo","year":"2019","unstructured":"Angiolillo DJ, Bhatt DL, Lanza F, Cryer B, Dong JF, Jeske W, et al. Pharmacokinetic\/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study. J Thromb Thrombolysis. 2019;48:554\u201362.","journal-title":"J Thromb Thrombolysis"},{"key":"7311_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/ajg.2010.436","volume":"106","author":"B Cryer","year":"2011","unstructured":"Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK. Low-dose Aspirin-induced ulceration is attenuated by Aspirin-Phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol. 2011;106:272\u20137.","journal-title":"Am J Gastroenterol"},{"key":"7311_CR15","first-page":"6688","volume":"15","author":"LM Lichtenberger","year":"2018","unstructured":"Lichtenberger LM, Phan T, Fang D, Dial EJ. Chemoprevention with phosphatidylcholine non-steroidal anti-inflammatory drugs in vivo and in vitro. Oncol Lett. 2018;15:6688\u201394.","journal-title":"Oncol Lett"},{"key":"7311_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/carcin\/20.1.51","volume":"20","author":"SR Ritland","year":"1999","unstructured":"Ritland SR, Gendler SJ. Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis. 1999;20:51\u20138.","journal-title":"Carcinogenesis"},{"key":"7311_CR17","first-page":"4316","volume":"57","author":"WJ Wechter","year":"1997","unstructured":"Wechter WJ, Kantoci D, Murray ED Jr, Quiggle DD, Leipold DD, Gibson KM, et al. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC (min)\/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res. 1997;57:4316\u201324.","journal-title":"Cancer Res"},{"key":"7311_CR18","first-page":"5040","volume":"60","author":"RF Jacoby","year":"2000","unstructured":"Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 2000;60:5040\u20134.","journal-title":"Cancer Res"},{"key":"7311_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1089\/jir.2010.0051","volume":"31","author":"EA Murphy","year":"2011","unstructured":"Murphy EA, Davis JM, McClellan JL, Gordon BT, Carmichael MD. Curcumin\u2019s effect on intestinal inflammation and tumorigenesis in the ApcMin\/+ mouse. J Interf Cytokine Res. 2011;31:219\u201326.","journal-title":"J Interf Cytokine Res"},{"key":"7311_CR20","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/carcin\/18.10.1905","volume":"18","author":"JE Paulsen","year":"1997","unstructured":"Paulsen JE, Elvsaas IK, Steffensen IL, Alexander J. A fish oil derived concentrate enriched in eicosapentaenoic and docosahexaenoic acid as ethyl ester suppresses the formation and growth of intestinal polyps in the min mouse. Carcinogenesis. 1997;18:1905\u201310.","journal-title":"Carcinogenesis"},{"key":"7311_CR21","first-page":"4267","volume":"57","author":"CH Chiu","year":"1997","unstructured":"Chiu CH, McEntee MF, Whelan J. Sulindac causes rapid regression of preexisting tumors in min\/+ mice independent of prostaglandin biosynthesis. Cancer Res. 1997;57:4267\u201373.","journal-title":"Cancer Res"},{"key":"7311_CR22","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S0016-5085(98)70305-1","volume":"114","author":"CJ Barnes","year":"1998","unstructured":"Barnes CJ, Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli min mouse model with aspirin. Gastroenterology. 1998;114:873\u20137.","journal-title":"Gastroenterology"},{"key":"7311_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1054\/plef.2000.0154","volume":"62","author":"CH Chiu","year":"2000","unstructured":"Chiu CH, McEntee MF, Whelan J. Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc (min\/+)mice. Prostaglandins Leukot Essent Fatty Acids. 2000;62:269\u201375.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"7311_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0039-6060(98)70124-2","volume":"124","author":"NN Mahmoud","year":"1998","unstructured":"Mahmoud NN, Dannenberg AJ, Mestre J, Bilinski RT, Churchill MR, Martucci C, et al. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery. 1998;124:225\u201331.","journal-title":"Surgery"},{"key":"7311_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1471-2407-2-19","volume":"2","author":"BK Reuter","year":"2002","unstructured":"Reuter BK, Zhang XJ, Miller MJS. Therapeutic utility of aspirin in the ApcMin\/+ murine model of colon carcinogenesis. BMC Cancer. 2002;2:19.","journal-title":"BMC Cancer"},{"key":"7311_CR26","first-page":"7060","volume":"61","author":"OJ Sansom","year":"2001","unstructured":"Sansom OJ, Stark LA, Dunlop MG, Clarke AR. Suppression of intestinal and mammary neoplasia by lifetime administration of aspirin in Apc (min\/+) and Apc (min\/+), Msh2(\u2212\/\u2212) mice. Cancer Res. 2001;61:7060\u20134.","journal-title":"Cancer Res"},{"key":"7311_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5582\/ddt.8.25","volume":"8","author":"R Wang","year":"2014","unstructured":"Wang R, Wang Y, Gao Z, Qu X. The comparative study of acetyl-11-keto-beta-boswellic acid (AKBA) and aspirin in the prevention of intestinal adenomatous polyposis in APC (min\/+) mice. Drug Discov Ther. 2014;8:25\u201332.","journal-title":"Drug Discov Ther"},{"key":"7311_CR28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10689-016-9901-9","volume":"15","author":"PM Lynch","year":"2016","unstructured":"Lynch PM. Chemoprevention of familial adenomatous polyposis. Familial Cancer. 2016;15:467\u201375.","journal-title":"Familial Cancer"},{"key":"7311_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27\u201331.","journal-title":"J Basic Clin Pharm"},{"key":"7311_CR30","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1158\/1535-7163.MCT-16-0074","volume":"15","author":"Y Huang","year":"2016","unstructured":"Huang Y, Lichtenberger LM, Taylor M, Bottsford-Miller JN, Haemmerle M, Wagner MJ, et al. Antitumor and Antiangiogenic effects of Aspirin-PC in ovarian Cancer. Mol Cancer Ther. 2016;15:2894\u2013904.","journal-title":"Mol Cancer Ther"},{"key":"7311_CR31","unstructured":"Sulindac Compound Summary. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Sulindac. Accessed 8 Apr 2020."},{"key":"7311_CR32","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1084\/jem.190.4.445","volume":"190","author":"SJ Shiff","year":"1999","unstructured":"Shiff SJ, Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med. 1999;190:445\u201350.","journal-title":"J Exp Med"},{"key":"7311_CR33","doi-asserted-by":"publisher","first-page":"38816","DOI":"10.18632\/oncotarget.5558","volume":"6","author":"Y Pan","year":"2015","unstructured":"Pan Y, Jiang Y, Tan L, Ravoori MK, Gagea M, Kundra V, et al. Deletion of cyclooxygenase-2 inhibits K-ras-induced lung carcinogenesis. Oncotarget. 2015;6:38816\u201326.","journal-title":"Oncotarget"},{"key":"7311_CR34","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMoa012015","volume":"346","author":"FM Giardiello","year":"2002","unstructured":"Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med. 2002;346:1054\u20139.","journal-title":"N Engl J Med"},{"key":"7311_CR35","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1158\/1055-9965.EPI-05-0112","volume":"14","author":"JJ Koornstra","year":"2005","unstructured":"Koornstra JJ, Rijcken FE, Oldenhuis CN, Zwart N, van der Sluis T, Hollema H, et al. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients. Cancer Epidemiol Biomark Prev. 2005;14:1608\u201312.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"7311_CR36","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/sj.bjc.6601505","volume":"90","author":"EM Boon","year":"2004","unstructured":"Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van der Neut R, et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer. 2004;90:224\u20139.","journal-title":"Br J Cancer"},{"key":"7311_CR37","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00384-013-1667-z","volume":"28","author":"L Brand","year":"2013","unstructured":"Brand L, Munding J, Pox CP, Ziebarth W, Reiser M, Huppe D, et al. Ss-catenin, cox-2 and p53 immunostaining in colorectal adenomas to predict recurrence after endoscopic polypectomy. Int J Color Dis. 2013;28:1091\u20138.","journal-title":"Int J Color Dis"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07311-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07311-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07311-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T23:27:28Z","timestamp":1631230048000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07311-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7311"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07311-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"3 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures were reviewed and approved by MD Anderson\u2019s Institutional Animal Care and Use Committee under Dr. David Menter\u2019s mouse protocol number 00001187.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Lichtenberger is the scientific co-founder of PLx Pharma Inc., and contact PI for the NCI STTR grant, which funded parts of this research (2R42CA171408-02A1). Dr. Sebastian is a member of the medical advisory board of Optrascan. All other authors declare they have no completing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"871"}}